Key result
Type 2 diabetes linked to ~54% higher CV event risk after permanent pacemaker implantation.
Why the study?
Type 2 diabetes was associated with higher risk for permanent pacemaker implantation, but clinical outcomes between diabetic and non-diabetic PPM patients were unclear.
Does the presence of diabetes increase the risk of cardiovascular events in patients receiving permanent pacemakers?
Cohort (n=1,742)
No
Does the presence of diabetes increase the risk of cardiovascular events in patients receiving permanent pacemakers?
In patients receiving a permanent pacemaker, the presence of diabetes is associated with a 1.54-fold increased risk of cardiovascular events, driven primarily by heart failure hospitalizations.
Type 2 diabetes may increase post-PPM cardiovascular events; hypothesis-generating and should not yet change practice.
Background: Type 2 diabetes was associated with higher risk for permanent pacemaker (PPM) implantation. We aimed to compare the clinical outcomes between diabetic and non-diabetic patients receiving PPM treatment. Methods: Between January 2003 and December 2017, 1742 patients receiving naïve PPM treatment comprised this retrospective cohort study and were categorized into two groups by the presence or absence of diagnosis of diabetes: diabetic group (n=632, 36.3%) and non-diabetic group (n=1110, 63.7%). The primary outcome was cardiovascular events including heart failure (HF) hospitalization and acute myocardial infarction (AMI). Propensity score matching (PSM) was applied to reduce selection bias between the study groups. Results: During a mean follow-up of 7.8 ± 4.8 years, there were 264 cardiovascular events. A total of 746 patients with a 1:1 paired ratio between diabetic and non-diabetic groups were analyzed in the propensity score-matched series. After PSM, the incidence of cardiovascular events was higher in the diabetic group compared to the non-diabetic group (18.8% vs. 12.3%, P=0.015). Moreover, the incidence of HF hospitalization was higher in the diabetic patients compared to the non-diabetic patients (15.3% vs. 10.2%, P=0.037), whereas the incidence of AMI did not differ between the diabetic and non-diabetic groups (3.5% vs. 2.1%, P=0.268). After adjustments for covariates in multiple Cox regression analysis, diabetes remained as an independent predictor for cardiovascular events [hazard ratio, 1.54; 95% confidence interval, 1.04-2.29; P=0.031].Conclusions:In this cohort study of patients with naïve PPMs implantation, diabetes increased 1.54-fold risk of cardiovascular events in PPM recipients, especially for HF hospitalization.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted a cohort in Naïve permanent pacemaker (PPM) implantation (n=1,742). Type 2 diabetes vs. Non-diabetic was evaluated on Cardiovascular events (heart failure hospitalization and acute myocardial infarction) (HR 1.54, 95% CI 1.04-2.29, p=0.031). Type 2 diabetes increased the risk of cardiovascular events by 1.54-fold compared to non-diabetic patients following permanent pacemaker implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: